Corbus Pharmaceuticals (CRBP) has issued an update.
Corbus Pharmaceuticals Holdings, Inc. announced promising results from a Phase 1 clinical trial of SYS6002 for treating advanced solid tumors at the ASCO Annual Conference. Conducted in China, the trial showed the drug was well tolerated with mostly low-grade adverse effects and no severe toxicities. Notably, significant anti-tumor responses were observed, with an overall response rate of 44% in metastatic urothelial cancer patients and 43% in cervical cancer patients. The data suggest an encouraging safety and efficacy profile for SYS6002, with ongoing trials to further evaluate its potential as a cancer therapy.
For a thorough assessment of CRBP stock, go to TipRanks’ Stock Analysis page.
